Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients (2012)
- Authors:
- USP affiliated authors: ANDRADE, JURANDYR MOREIRA DE - FMRP ; TIÉZZI, DANIEL GUIMARÃES - FMRP ; PERIA, FERNANDA MARIS - FMRP
- Unidade: FMRP
- DOI: 10.1007/s12032-010-9793-8
- Subjects: ESTUDOS RETROSPECTIVOS; NEOPLASIAS MAMÁRIAS; QUIMIOTERAPIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Medical Oncology
- ISSN: 1357-0560
- Volume/Número/Paginação/Ano: v. 29, n. 1, p. 33-38, 2012
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- Versão do Documento: Versão submetida (Pré-print)
-
Status: Artigo possui versão em acesso aberto em repositório (Green Open Access) -
ABNT
BRITO, Luiz Gustavo Oliveira et al. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Medical Oncology, v. 29, n. 1, p. 33-38, 2012Tradução . . Disponível em: https://doi.org/10.1007/s12032-010-9793-8. Acesso em: 15 mar. 2026. -
APA
Brito, L. G. O., Andrade, J. M. de, Lins-Almeida, T., Zola, F. E., Pinheiro, M. N., Marana, H. R. C., et al. (2012). Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Medical Oncology, 29( 1), 33-38. doi:10.1007/s12032-010-9793-8 -
NLM
Brito LGO, Andrade JM de, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HRC, Tiezzi DG, Peria FM. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients [Internet]. Medical Oncology. 2012 ; 29( 1): 33-38.[citado 2026 mar. 15 ] Available from: https://doi.org/10.1007/s12032-010-9793-8 -
Vancouver
Brito LGO, Andrade JM de, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HRC, Tiezzi DG, Peria FM. Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients [Internet]. Medical Oncology. 2012 ; 29( 1): 33-38.[citado 2026 mar. 15 ] Available from: https://doi.org/10.1007/s12032-010-9793-8 - Breast conserving surgery after neoadjuvant therapy for large primary breast cancer
- Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
- Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy
- Mouse renal 4T1 cell engraftment as a model to study the influence of hypoxia in breast cancer progression
- Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
- Trastuzumab-induced myocardiotoxicity mimicking acute coronary syndrome
- Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer
- Genetic profile analysis of tumor stem cells in locally advanced breast cancer
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
